Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Total Current Liabilities: 2017-2025

Historic Total Current Liabilities for Cidara Therapeutics (CDTX) over the last 9 years, with Sep 2025 value amounting to $95.8 million.

  • Cidara Therapeutics' Total Current Liabilities rose 116.15% to $95.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $95.8 million, marking a year-over-year increase of 116.15%. This contributed to the annual value of $49.6 million for FY2024, which is 26.50% down from last year.
  • According to the latest figures from Q3 2025, Cidara Therapeutics' Total Current Liabilities is $95.8 million, which was up 196.55% from $32.3 million recorded in Q2 2025.
  • Cidara Therapeutics' 5-year Total Current Liabilities high stood at $95.8 million for Q3 2025, and its period low was $32.3 million during Q2 2025.
  • Over the past 3 years, Cidara Therapeutics' median Total Current Liabilities value was $48.8 million (recorded in 2025), while the average stood at $53.3 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first declined by 26.50% in 2024, then spiked by 116.15% in 2025.
  • Over the past 5 years, Cidara Therapeutics' Total Current Liabilities (Quarterly) stood at $34.0 million in 2021, then grew by 21.70% to $41.4 million in 2022, then soared by 62.85% to $67.4 million in 2023, then fell by 26.50% to $49.6 million in 2024, then surged by 116.15% to $95.8 million in 2025.
  • Its Total Current Liabilities stands at $95.8 million for Q3 2025, versus $32.3 million for Q2 2025 and $48.8 million for Q1 2025.